- Legislation Introduced to Codify Stem Cell Rules
- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- The Top Science Progress Features of 2009
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
Stem Cells: A Life Sciences Crucible
Next week is bookended by science policy events at CAP: innovation and patent reform on Monday and stem cells on Friday:
A Life Sciences Crucible
Stem Cell Science and Innovation Done Responsibly and Ethically
Featured Panelists:
Amy Comstock Rick, President, Coalition for the Advancement of Medical Research
John Gearhart, Director, Institute for Regenerative Medicine and the James W. Effron University Professor, University of Pennsylvania
Moderated By:
Michael J. Rugnetta, Fellows Assistant, Progressive Bioethics Initiative, Center for American Progress
The time has come for the U.S. to renew its promise of global life sciences leadership. With the ascendancy of the Obama administration and a more progressive Congress, the opportunity for renewal has never been greater. The United States must now stake its claim as the world leader in regenerative medicine, which is almost certain to become a vital component of cutting edge biomedical innovation in the 21st century. To ensure that the research in this newly emerging field of the life sciences is conducted responsibly and ethically, the federal government must reform its stem cell research policy and fund embryonic stem cell research in a manner that is robust and comprehensive as well as cautious and principled.
The greatest potential for regenerative medicine lies in the ability of scientists to tap into the process of cell differentiation and development. This can only be achieved by tracing the development of human cells from the very beginning. To do so, scientists need to conduct research on embryonic stem cells so that they can discover how these all-purpose “pluripotent” cells can change into any one of over two hundred different cell types in the human body. Indeed, this research will provide us with unprecedented insights into human development, how it can go wrong, and how it can be fixed—perhaps leading to 21st century medicine’s biggest paradigm shift.
Please join us for the release of CAP’s new report, “A Life Sciences Crucible: Stem Cell Science and Innovation Done Responsibly and Ethically.” The release event will include a panel discussion featuring Amy Comstock Rick of the Coalition for Advancement of Medical Research and John Gearhart, professor of cell biology at the University of Pennsylvania. The event will be moderated by Michael J. Rugnetta, the Fellows Assistant for the Progressive Bioethics Initiative at the Center for American Progress.
Friday, January 16, 2009
Program: 12:00pm to 1:30pm
Admission is free.
A light lunch will be served at 11:30 a.m.
Center for American Progress
1333 H St. NW, 10th Floor
Washington, DC 20005
Map & Directions
Nearest Metro: Blue/Orange Line to McPherson Square or Red Line to Metro Center
For more information, please call 202-682-1611.
Comments on this article
